PDCD1 and cancer: Although anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has achieved amazing clinical outcomes for some patients with advanced cancer, therapy resistance has raised several therapeutic challenges, including identifying additional pathways to target.